Dr. Ascierto on the COLUMBUS Trial in Melanoma

Source: Onc Live, June 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.

COLUMBUS was a phase III trial of encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in patients with BRAF-mutant melanoma. Median overall survival was 33.6 months (95% CI, 24.4-39.2) with encorafenib plus binimetinib, 23.5 months (95% CI, 19.6-33.6) with encorafenib, and 16.9 months (95% CI, 14.0-24.5) with vemurafenib.